Abbott Laboratories
NYSE:ABTMedical - Devices
-$0.51 today
- Market cap
- $180.95B
- Beta
- 0.62
- P/E (TTM)
- 24.5
- EPS (TTM)
- $3.59
- Dividend yield
- 2.77%
Volume 7.02M
Average 13.17M
ABT Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Abbott LaboratoriesNYSE: ABT
Gross Profit · Q3 FY2026 · quarter ended Sep 2026
Gross profit grows in line with its trailing trend
Q3 FY2026 gross profit of $7.42B rose 17.1% year over year, ahead of the +16.4% change in trailing-twelve-month gross profit. Sequentially, it rose 1.6% from the prior quarter. Over 3 fiscal years it compounded at +3.3% a year.
Context
- Gross profit amounted to 55.5% of revenue in FY2025, up 4.7 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +17.1% holds above the trailing-twelve-month pace of +16.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 24.61B USD
- Year-over-year change
- +15.4%
- 4-year CAGR
- +1.5%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.61B | +15.4% |
| FY2024 | 2024-12-31 | 21.33B | +6.4% |
| FY2023 | 2023-12-31 | 20.04B | -10.2% |
| FY2022 | 2022-12-31 | 22.32B | -3.8% |
| FY2021 | 2021-12-31 | 23.21B | — |
Gross Profit vs competitors
How ABT compares with its peers on the latest reported figures
- ABT's LTM Sep 2026 gross profit of $27.55B is the 2nd highest of the 10 companies compared; the peer median is $15.01B.
- Its year-over-year change of +16.4% is the 2nd highest of 10, against a peer median of +10.8%.
- Gross profit amounts to 57.1% of revenue for ABT, versus a peer median of 65.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $68.35B | +9.0% | +4.9% | 68.8% | |
| LTM Sep 2026 | $27.55B | +16.4% | +3.3% | 57.1% | |
| LTM Jul 2026 | $25.04B | +15.4% | +4.9% | 66.7% | |
| LTM Sep 2026 | $19.62B | +10.8% | -1.4% | 41.4% | |
| LTM Jun 2026 | $16.84B | +12.4% | +13.3% | 65.2% | |
| LTM Sep 2026 | $15.01B | +0.8% | -2.6% | 58.6% | |
| LTM Jun 2026 | $14.94B | +27.8% | +21.5% | 71.2% | |
| LTM Sep 2026 | $9.51B | -4.2% | +4.1% | 47.0% | |
| LTM Jun 2026 | $8.69B | +4.7% | +4.7% | 42.9% | |
| LTM Jun 2026 | $5.08B | +13.2% | +4.0% | 78.0% | |
| Peer median (excluding ABT) | $15.01B | +10.8% | +4.7% | 65.2% | |
Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.08B | 43.65B | 40.11B | 41.95B | 44.33B |
| Cost of Revenue | 19.86B | 21.33B | 20.07B | 20.63B | 19.72B |
| Gross Profit | 23.21B | 22.32B | 20.04B | 21.33B | 24.61B |
| Gross Margin | 53.9% | 51.1% | 50.0% | 50.8% | 55.5% |
| Research & Development | 2.74B | 2.85B | 2.72B | 2.82B | 2.96B |
| Selling, General & Admin | 11.28B | 11.11B | 10.88B | 11.65B | 12.38B |
| Operating Expenses | 14.01B | 13.96B | 13.6B | 14.47B | 16.59B |
| Depreciation & Amortization | 3.54B | 3.27B | 3.24B | 3.22B | 3.12B |
| EBITDA | 12.16B | 11.89B | 10.61B | 10.83B | 11.92B |
| EBITDA Margin | 28.2% | 27.2% | 26.4% | 25.8% | 26.9% |
| Operating Income | 9.2B | 8.36B | 6.44B | 6.83B | 8.05B |
| Operating Margin | 21.4% | 19.2% | 16.0% | 16.3% | 18.2% |
| Interest Income | 43M | 183M | 385M | 344M | 230M |
| Interest Expense | 410M | 315M | 698M | 603M | 341M |
| Other Income / Expenses | (989M) | (56M) | 229M | 188M | 418M |
| Income Before Tax | 8.21B | 8.31B | 6.66B | 7.01B | 8.47B |
| Pre-Tax Margin | 19.1% | 19.0% | 16.6% | 16.7% | 19.1% |
| Income Tax Expense | 1.14B | 1.37B | 941M | (6.39B) | 1.94B |
| Net Income | 7.07B | 6.93B | 5.72B | 13.4B | 6.52B |
| Net Margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
| EPS (Basic) | 3.97 | 3.94 | 3.30 | 7.67 | 3.74 |
| EPS (Diluted) | 3.94 | 3.91 | 3.27 | 7.64 | 3.72 |
| Weighted Avg Shares | 1.78B | 1.75B | 1.73B | 1.73B | 1.75B |
| Weighted Avg Shares (Diluted) | 1.79B | 1.76B | 1.75B | 1.75B | 1.75B |
Abbott Laboratories
NYSE:ABT
Intrinsic Alpha fair value
Locked
Current Price
$104.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.